SCHEMBL2653252

SCHEMBL2653252

Nc1cc(C2CC2)ccc1Nc1cccc(-c2ccon2)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.41
DHODH Q02127 11/20 0.38
P2RX3 P56373 1/20 0.35
BACE1 P56817 1/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
GFER P55789 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.32
TDO2 P48775 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PRKCI P41743 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655091 0.87 SYK (0.38) SYKP2RX3BACE1ALDH1A1GAA
SCHEMBL2654386 0.82 DHODH (0.39) SYKDHODHMAPTMEN1KMT2A
SCHEMBL2654381 0.77 DHODH (0.47) SYKDHODHBACE1MEN1TDO2
SCHEMBL2655100 0.76 GAA (0.46) SYKALDH1A1GAAMAPTKDM4E
SCHEMBL2654514 0.74 SYK (0.42) SYKDHODHPRKCI
SCHEMBL2655959 0.74 DHODH (0.40) DHODHBACE1
SCHEMBL2654545 0.70 L3MBTL1 (0.38) SYKP2RX3MAPTMEN1KMT2A
SCHEMBL2652971 0.65 TDO2 (0.40) SYKBACE1ALDH1A1GAAMAPT
SCHEMBL29433480 0.65 MEN1 (0.49) ALDH1A1MAPTKDM4EMEN1GFER
SCHEMBL1015565 0.65 MEN1 (0.49) ALDH1A1MAPTKDM4EMEN1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7335777-B2 Benzimidazole derivatives and their use for modulating the GABAA receptor complex NEUROSEARCH A/S (DK) 2008-02-26 US disclosed
EP-1613312-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA A RECEPTOR COMPLEX NEUROSEARCH AS (DK) 2008-02-20 EP disclosed
US-20060148856-A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex ANIONA APS (DK) 2006-07-06 US disclosed
EP-1613312-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA sb A /sb RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-01-11 EP disclosed
WO-2004087137-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148856-A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex GABRB2, GABRB1, GABRB3 SYK 3117/4885DHODH 3475/4885P2RX3 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.